QT
EPZM

Quantamental Technologies’s Epizyme, Inc EPZM Stock Holding History

Quantamental Technologies’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-6,934
Closed -$43K – 1877
2018
Q4 		$43K Buy
+6,934
New +$53K 0.03% 818

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Quantamental Technologies's EPZM Position: Q1 2019 in Review

Quantamental Technologies sold out of Epizyme, Inc (EPZM) in Q1 2019, closing a stake of 6,934 shares — an estimated $43K sold.

Quantamental Technologies first reported a position in EPZM in Q4 2018 and held it in 1 quarter. The position peaked at $43K in Q4 2018. 121 funds tracked by Wall St. Rank hold EPZM as of Q1 2019.

  • Quantamental Technologies reported no remaining Epizyme, Inc position as of Q1 2019 after selling out during the quarter.
  • Quantamental Technologies sold 6,934 Epizyme, Inc shares in Q1 2019, an estimated $43K.
  • Quantamental Technologies first reported a position in Epizyme, Inc in Q4 2018 and held it in 1 quarter.
  • Quantamental Technologies's Epizyme, Inc position peaked at $43K in Q4 2018.
  • 121 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2019.

Based on Quantamental Technologies's 13F filing for Q1 2019, filed 29 Apr 2019.